The PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, cross-talk, and therapies

PTEN Deficiency Contributes to the Development and Progression of Head and Neck Cancer

(2015) Cristiane H Squarize et al.   NEOPLASIA

HSP90 Inhibitor SNX5422/ 2112 Targets the Dysregulated Signal and Transcription Factor Network and Malignant Phenotype of Head and Neck Squamous Cell Carcinoma

(2014) Jay A. Friedman et al.   Translational Oncology

Astaxanthin inhibits NF-κB and Wnt/β-catenin signaling pathways via inactivation of Erk/MAPK and PI3K/Akt to induce intrinsic apoptosis in a hamster model of oral cancer

(2013) K. Kavitha et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

Cancer statistics, 2013

(2013) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer

(2013) Matthew G. Fury et al.   CANCER

PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity Is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer

(2013) A. Herzog et al.   CLINICAL CANCER RESEARCH

Impact of targeting insulin-like growth factor signaling in head and neck cancers

(2013) Kirsten H. Limesand et al.   GROWTH HORMONE & IGF RESEARCH

A Phase 1 Study of Everolimus + Weekly Cisplatin + Intensity Modulated Radiation Therapy in Head-and-Neck Cancer

(2013) Matthew G. Fury et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins

(2013) Stephen B. Keysar et al.   Molecular Oncology

Rapamycin Inhibits IGF-1-Mediated Up-Regulation of MDM2 and Sensitizes Cancer Cells to Chemotherapy

(2013) Wei Du et al.   PLoS One

mTORC1 Phosphorylation Sites Encode Their Sensitivity to Starvation and Rapamycin

(2013) S. A. Kang et al.   SCIENCE

Cancer Genome Landscapes

(2013) B. Vogelstein et al.   SCIENCE

Exploiting the Head and Neck Cancer Oncogenome: Widespread PI3K-mTOR Pathway Alterations and Novel Molecular Targets

(2013) R. Iglesias-Bartolome et al.   Cancer Discovery

Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers

(2013) V. W. Y. Lui et al.   Cancer Discovery

Integrative Genomic Characterization of Oral Squamous Cell Carcinoma Identifies Frequent Somatic Drivers

(2013) C. R. Pickering et al.   Cancer Discovery

High Frequency of Activating PIK3CA Mutations in Human Papillomavirus–Positive Oropharyngeal CancerPIK3CA in HPV+ Oropharyngeal Squamous Cell Carcinoma

(2013) Anthony C. Nichols   JAMA Otolaryngology-Head & Neck Surgery

Copy Number Amplification of the PIK3CA Gene Is Associated with Poor Prognosis in Non-lymph node metastatic Head and Neck Squamous Cell Carcinoma

(2012) Toshihito Suda et al.   BMC CANCER

Oncogenic PI3K Mutations Lead to NF- B-Dependent Cytokine Expression following Growth Factor Deprivation

(2012) J. E. Hutti et al.   CANCER RESEARCH

A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors

(2012) D. S. Hong et al.   CLINICAL CANCER RESEARCH

Targeting Stat3 Abrogates EGFR Inhibitor Resistance in Cancer

(2012) M. Sen et al.   CLINICAL CANCER RESEARCH

Mechanisms for Kinase-mediated Dimerization of the Epidermal Growth Factor Receptor

(2012) Chafen Lu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

PI3K signalling: the path to discovery and understanding

(2012) Bart Vanhaesebroeck et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors

(2012) Dalia Ercan et al.   Cancer Discovery

Receptor Tyrosine Kinases and TLR/IL1Rs Unexpectedly Activate Myeloid Cell PI3Kγ, A Single Convergent Point Promoting Tumor Inflammation and Progression

(2011) Michael C. Schmid et al.   CANCER CELL

Decreased Lymphangiogenesis and Lymph Node Metastasis by mTOR Inhibition in Head and Neck Cancer

(2011) V. Patel et al.   CANCER RESEARCH

Loss of TGF-β signaling and PTEN promotes head and neck squamous cell carcinoma through cellular senescence evasion and cancer-related inflammation

(2011) Y Bian et al.   ONCOGENE

Mutational analysis of PTEN/PIK3CA/AKT pathway in oral squamous cell carcinoma

(2011) Yoram Cohen et al.   ORAL ONCOLOGY

Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers

(2011) L. G. T. Morris et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Scaling rules for diffusive drug delivery in tumor and normal tissues

(2011) James W. Baish et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1

(2011) N. Agrawal et al.   SCIENCE

The Mutational Landscape of Head and Neck Squamous Cell Carcinoma

(2011) N. Stransky et al.   SCIENCE

PI3K  Inhibitors in Cancer: Rationale and Serendipity Merge in the Clinic

(2011) D. A. Fruman et al.   Cancer Discovery

Immunity, Inflammation, and Cancer

(2010) Sergei I. Grivennikov et al.   CELL

MAPK and PI3K signalling differentially regulate angiogenic and lymphangiogenic cytokine secretion in squamous cell carcinoma of the head and neck

(2010) Sutima Luangdilok et al.   EUROPEAN JOURNAL OF CANCER

EGFR–PI3K–AKT–mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy

(2010) Christian Freudlsperger et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Pharmacodynamic evaluation of temsirolimus in patients with newly diagnosed advanced-stage head and neck squamous cell carcinoma

(2010) Oleksandr Ekshyyan et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

The PI3K Pathway As Drug Target in Human Cancer

(2010) Kevin D. Courtney et al.   JOURNAL OF CLINICAL ONCOLOGY

The emerging mechanisms of isoform-specific PI3K signalling

(2010) Bart Vanhaesebroeck et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

A complex interplay between Akt, TSC2 and the two mTOR complexes: Figure 1

(2009) Jingxiang Huang et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Rapamycin Prevents Early Onset of Tumorigenesis in an Oral-Specific K-ras and p53 Two-Hit Carcinogenesis Model

(2009) A. R. Raimondi et al.   CANCER RESEARCH

Proteomic Signatures of Epidermal Growth Factor Receptor and Survival Signal Pathways Correspond to Gefitinib Sensitivity in Head and Neck Cancer

(2009) F. G. Pernas et al.   CLINICAL CANCER RESEARCH

Tumours with PI3K activation are resistant to dietary restriction

(2009) Nada Y. Kalaany et al.   NATURE

Targeting the phosphoinositide 3-kinase pathway in cancer

(2009) Pixu Liu et al.   NATURE REVIEWS DRUG DISCOVERY

Regulation of cell polarity during epithelial morphogenesis

(2008) Fernando Martin-Belmonte et al.   CURRENT OPINION IN CELL BIOLOGY

Akt-dependent regulation of NF- B is controlled by mTOR and Raptor in association with IKK

(2008) H. C. Dan et al.   GENES & DEVELOPMENT

A signal network involving coactivated NF-κB and STAT3 and altered p53 modulates BAX/BCL-XL expression and promotes cell survival of head and neck squamous cell carcinomas

(2008) Tin Lap Lee et al.   INTERNATIONAL JOURNAL OF CANCER

The regulation of cell motility and chemotaxis by phospholipid signaling

(2008) V. Kolsch et al.   JOURNAL OF CELL SCIENCE

Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration

(2008) Mariona Graupera et al.   NATURE

PI3K pathway alterations in cancer: variations on a theme

(2008) T L Yuan et al.   ONCOGENE

Dysregulated molecular networks in head and neck carcinogenesis

(2008) Alfredo A. Molinolo et al.   ORAL ONCOLOGY

Class 1A PI3K regulates vessel integrity during development and tumorigenesis

(2008) T. L. Yuan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA